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doi:10.1016/j.jmii.2011.09.025Background/Purpose: Enterovirus 71 (EV71) infection may cause severe neurological and
cardiopulmonary complications, especially in preschool children. This study is to investigate
the seroprevalence and seroconversion of EV71, and the crossprotection of EV71 antibody
against other enteroviruses among kindergarteners.
Methods: Overall 228 children in a public kindergarten were enrolled during two academic
years, 2006 and 2007, in Taipei, Taiwan and we measured their EV71 neutralizing antibody.
When the participants had herpangina; hand, foot and mouth disease (HFMD); febrile illness
or respiratory symptoms, throat swabs were sampled and processed for viral culture and
enterovirus real-time reverse transcriptase polymerase chain reaction (RT-PCR).
Questionnaires, completed by the participants’ guardians, surveyed the history of allergy
and annual incidence of symptoms related to enterovirus infection.
Results: Seropositive rates of EV71 were 20% (32/163) in 2006 and 6% (4/65) in 2007. The rate
of EV71 seropositivity increased with age (p < 0.01) in 2006 but it did not differ between
genders (p Z 0.14). No seroconversion was observed from 2006 to 2007. Herpanginaof Pediatrics, National Taiwan University Hospital, College of Medicine, National Taiwan University,
ipei, 100, Taiwan.
u.tw, ly7077@tpts6.seed.net.tw (L.-Y. Chang).
an Society of Microbiology. Published by Elsevier Taiwan LLC. All rights reserved.
Enteroviruses among kindergarteners 97occurred in 64% of children with EV71 seropositivity and 48% of those without EV71 antibodies
(pZ 0.12). Non-71 enterovirus infection, confirmed by viral study, occurred in 53% (19/36) of
the EV71-seropositive children and in 53% (102/192) of EV71-seronegative children (pZ 0.89).
No participants had EV71 infection during the study period.
Conclusion: EV71 did not frequently circulate in Taipei City from September 2006 to June 2008.
Presence of EV71 neutralizing antibody was not associated with lower incidence of enterovirus
infection caused by non-71 serotypes.
Copyright ª 2011, Taiwan Society of Microbiology. Published by Elsevier Taiwan LLC. All rights
reserved.Introduction
Enterovirus 71 (EV71), discovered in the USA in 1969,
belongs to the family of Picornaviridae.1 Compared with
the other serotypes of enteroviruses, EV71 is well known
for its neurotropic characteristics of invading the nervous
system and it may cause acute flaccid syndrome,
encephalitis and meningitis.2 In the past 30 years,
outbreaks of EV71 infection have brought about great
casualties and socioeconomic burdens in the endemic
countries, such as Bulgaria (1975), Hungary (1977) and
Malaysia (1997).3e5 The most devastating outbreak caused
by EV71 occurred in Taiwan in 1998, resulting in 78 deaths
and 405 children with severe neurological complications.
The major causes of mortality and morbidity are cardio-
pulmonary failure and pulmonary edema/hemorrhage fol-
lowed by brainstem encephalitis, which more commonly
affect young children.6e8
Transmission in kindergartens and among family
members was considered an important pathway of disease
spread during the EV71 epidemic in Taiwan in 1998.9,10
Preschool children who attended kindergarten and day-
care centers had elevated rate of EV71 seropositivity.10 In
Singapore, Ooi et al. reported higher geometric mean titer
(46.8) of EV71 antibody in children aged 2e5 years
compared with mean titer (28.8) in children aged 6e12
years.11 This suggested that preschool children were more
frequently infected with EV71 than older children. More-
over, the surveillance in Taiwan indicated EV71 seroposi-
tivity increased with age.10 Annual seroconversion rate, an
indication of latest infection in previously uninfected
cohort, was 7e11% during 1989e1993 but the annual sero-
conversion rate markedly decreased to 4% in 1994 and to 3%
in 1997.10,12 Low seroconversion rate is therefore specu-
lated as a possible factor related to the EV71 epidemic in
1998.
Because enterovirus infection commonly occurs among
children, it has been a puzzle for decades that the severity
is diverse among individuals after infection. Research on
the foot-and-mouth disease virus revealed that a member
of Picornaviridae causing hand, foot and mouth disease
(HFMD)-like symptoms in cloven-hoofed animals, serum
IgM, acquired after foot-and-mouth disease virus infection,
neutralized the virus of other serotypes.13 Crossreactivity
has also been observed among human enteroviruses, for
example, after infection of coxsackievirus A9 the mono-
clonal antibody recognized coxsackievirus A21 and all three
serotypes of poliovirus but did not affect their infectivity.14
Therefore, the relation between crossreactivity andcrossprotection is still unclear. Clinical investigation is
therefore required to verify crossprotection among
different serotypes of enteroviruses.
Seroepidemiology provides information of great impor-
tance in the surveillance of EV71 activity. We thus con-
ducted this study to analyze the seropositivity and
seroconversion of EV71 in preschool children and to delin-
eate the possibility of crossprotection of EV71 antibody
against other serotypes of enteroviruses.
Methods
A. Case enrollment and study design
1. Agreement from the institutional review board of
National Taiwan University Hospital, and from the
education bureaus of Taipei city
The institutional review board of National Taiwan Univer-
sity Hospital approved this study and the education bureaus
of Taipei city also agreed to this study after reviewing the
project.
2. Enrollment of children and kindergartens
One public kindergarten located in Taipei City agreed to
this study. After informed consent was obtained from their
parents, we enrolled 228 preschool children (123 boys and
105 girls) in a kindergarten in Taipei City in the academic
year of 2006 (September 2006eJune 2007) and academic
year of 2007 (September 2007eJune 2008). Among the 228
children, 163 children (91 boys and 72 girls) were enrolled
in year 2006, and 65 new participants (33 boys and 32 girls)
and 75 participants from year 2006 enrolled in the following
academic year. These children were aged between 2 years
7 months and 6 years 7 months. Their growth and neuro-
logical development were within normal limits. A flow chart
of the study design is shown in Fig. 1.
3. Demography, family history and past history
All the guardians of the enrolled preschool children
received a questionnaire to record their children’s age,
gender, medical history, allergy history, vaccine history and
history of developing herpangina and HFMD during each
academic year. Allergy history included atopic dermatitis,
allergic rhinitis, hyperactive airway and asthma. The age of
a participant was defined as the age of the child at the
beginning of the academic year (September 1st of each
academic year).
Figure 1. Flow chart of study design. After retrieving the
questionnaires, all participants received blood tests for
enterovirus 71 (EV71) neutralizing antibodies (Ab). If the chil-
dren presented symptoms of respiratory tract infection, then
throat swabs were collected and sent for real-time reverse
transcriptase polymerase chain reaction (RT-PCR) and viral
cultures.
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The kindergarten nurse recorded the daily medication
and the causes of receiving medication of every kinder-
gartener. If the children had fever or symptoms of entero-
virus infection, for example herpangina or HFMD, throat
swabs would be collected by study nurses and sent for viral
isolation and real-time reverse transcriptase polymerase
chain reaction (RT-PCR).
Regular physical examinations of the participants were
performed by several senior pediatricians every other
week. If the participants had symptoms of respiratory
infections or enterovirus infection (e.g., herpangina or
HFMD), the abnormal physical signs and clinical diagnoses
would be recorded and throat swabs would also be sampled
and sent for viral culture and RT-PCR.
B. Laboratory methods
1. Virus isolation and serotyping
Throat swabs were submitted for virus isolation. Samples
were inoculated into human embryonic fibroblast, LLC-
MK2, HEp-2 and rhabdomyosarcoma (RD) cell cultures.
When cytopathic effect involved more than 50% of the cell
monolayer, cells were scraped and subjected to indirect
fluorescent antibody staining with specific antibodies(Chemicon International Inc., Temecula, CA, USA) or typed
by VP1 sequencing.
2. Molecular diagnosis for enteroviruses by real-time
reverse transcriptase polymerase chain reaction
Total nucleic acid extraction from throat swabs was
performed using an Isolation Kit (RNA and DNA extraction
kit, Qiagen) according to the manufacturer’s guidelines
(Roche, MagNA Pure LC 2.0). Reverse transcription was
performed with first strand cDNA Synthesis Kit for RT-PCR
according to the manufacturer’s guidelines (Invitrogen,
Carlsbad, CA, USA). Real-time PCR for pan-enterovirus was
performed with primers and probes based on the highly
conserved region in the 50-untranslated region of the
enterovirus genome. The sequences of the primers (Geno-
mics BioSci & Tech, Taiwan) and probes (TIB MOLBIOL,
Germany) are listed as follows: forward primer,
50-TCCTCCGGCCCCTGAATG-30; reverse primer, 50-AATTGT-
CACCATAAGCAGCCA-30; PanEV probe (TaqMan), 6FAM-
AACCGACTACTTTGGGTGTCCGTGTTTCXT-PH.
3. Molecular typing of the circulating enteroviruses
during the surveillance
If there were positive results of enteroviral cytopathic
effect or enteroviral RT-PCR, further molecular typing
would be performed. Polymerase chain reaction (PCR)
followed by direct sequencing was performed. Three
genogroup-specific degenerate oligonucleotide primers
flanking VP1 region were made including EntAF TNCARGC
WGCNGARACNGG, EntAR outer ANGGRTTNGTNGMWGTY
TGCCA, EntAR inner GGNGGNACRWACATRTAYTG, EntBF
GCNGYNGARACNGGNCACAC, EntBR outer CTNGGRTTNGTN
GANGWYTGCC, EntBR inner CCNCCNGGBGGNAYRTACAT,
EntCF TNACNGCNGTNGANACHGG, EntCR outer TGCCANGTR
TANTCRTCCC and EntCR inner GCNCCWGGDGGNAYRTACAT.
PCR products were purified using the Gel/PCR DNA frag-
ments extraction kit (Geneaid) before sequencing and
direct sequencing was performed with the previous
genogroup-specific primers on 377 PE/ABI automatic
sequencer (Perkin-Elmer Cetus, Norwalk, Connecticut,
USA) with ABI Prism BigDye Termination Cycle Sequencing
Ready Reaction Kit (Applied Biosystems, Perkin-Elmer). The
serotype of enteroviruses was inferred by comparing the
partial VP1 sequence with VP1 sequences for all strains of
the 67 human enterovirus serotypes held in the public gene
database.
4. Blood sampling and measurement of EV71 neutralizing
antibodies
The participants were encouraged to donate a blood
sample annually after written consent was obtained from
their guardians. If the children did not have EV71 neutral-
izing antibody in academic year 2006, then a second blood
sample would be taken to investigate the EV71 serocon-
version rate in the next academic year.
The measurement of EV71 neutralizing antibody fol-
lowed the standard protocol for the neutralizing test on
microtiter plates. A mixture of serum and 50 mL EV71
solution, which contained 100 50% tissue culture-infective
Figure 2. Distribution and enterovirus 71 seropositivity of
participants in two academic years. In academic year 2006, 163
children were recruited. Among these participants, only those
without enterovirus 71 (EV71) antibodies (Ab) would receive
another blood test for serum Ab in academic year 2007 to
determine the seroconversion rate. Among 32 seropositive
children, half of them withdrew from the study in 2007. Eight
children attended elementary school and the rest transferred
to other schools; none of them had seroconversion. As for 131
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number AF119795), was incubated with RD cells at 35C in
a 5% carbon dioxide incubator. After an incubation period of
2 to 7 days, the neutralizing antibody titer was determined
at the time when cytopathic effect was observed in 1 50%
tissue culture-infective dose of the virus back titration
under an inverted microscope. The neutralizing antibody
titer is defined as the highest dilution of serum that
prevents the occurrence of cytopathic effect. Seroposi-
tivity is defined as EV71 neutralizing titer 8, and sero-
conversion of EV71 is defined as the change of EV71 from
seronegative to seropositive or a fourfold rise in the titer of
EV71 neutralizing antibodies.
C. Statistics
We compared the clinical course and outcome among
different serotypes of enteroviruses and compared the
serotypes in different years. We analyzed the rate of
enterovirus infections and the rate of herpangina/HFMD
between EV71-seropositive kindergarteners and EV71-
seronegative kindergarteners. The methods of statistical
analysis include the student t test and analysis of variance
for continuous variables, and appropriate c2 tests for
categorical data. A p value less than 0.05 was considered to
be significant. The data were analyzed with SAS 9.2
statistical software (SAS Institute, Inc, Cary, NC).seronegative children, 72 dropped out from the test in 2007
because 31 of them had transferred to other schools, 25
attended elementary school and 16 withdrew for personal
reasons. Overall 59 children with EV71 seronegative received
Ab testing in 2007. In academic year 2007, 65 children were
newly recruited and 4 cases were seropositive.Results
Demography
Overall 228 preschool children (123 boys, 105 girls) were
recruited in a kindergarten in Taipei City between
September 2006 and June 2008. The recruitment numbers
and EV71 seropositivity in each academic year are charted
in Fig. 2. In academic year 2006, 91 boys and 72 girls
participated, their mean age was 4.1  1.0 years and the
median age was 3.9 years. In academic year 2007, total
participants were 140 children, which included 75 partici-
pants who were enrolled in 2006 (16 seropositive and 59
seronegative) and 65 new participants, 33 boys and 32 girls.
The mean age of the new participants was 3.6  1.0 years
and the median age was 3.5 years.
Of the questionnaires 92% were retrieved. More than half
of the participants (51%) reported allergy history and 37%
had more than two allergic illnesses. Allergic rhinitis (47%)
was the most common allergic illness, followed by hyper-
reactive airway (26%), atopic dermatitis (23%), asthma
(10%) and allergic conjunctivitis (9%).
EV71 seropositive rates among genders and
different age groups
Seropositive rate of EV71 was 20% (32/163) in academic
year 2006 and 6% (4/65) for the 65 new participants in
academic year 2007. Although boys seemed to have
a higher incidence of EV71 seropositivity in both two years,
no significant gender difference was found (boy: 20%, girl:
11%; p Z 0.14). Age-specific EV71 seropositive rates inacademic year 2006 were 10% (2/20) for 2-year-old
children, 8% (5/60) for 3-year-old children, 33% (16/49) for
4-year-old children and 26% (9/34) for 5-year-old children
(p < 0.01). The result in 2006 indicated seropositive rate
increased with age. In academic year 2007, only 4 children
among the 65 new participants (6%) were seropositive (3
boys and 1 girl at the age of 3 years).
Seroconversion rate
Among the cohort of 59 children with seronegative status in
the academic year of 2006, no seroconversion of EV71
antibody was found in the academic year of 2007 as Fig. 2
shows.
Rates of herpangina and HFMD during the
surveillance of the two academic years
None of the participants had HFMD during the study period.
As for the incidence of herpangina, 55% (89/163) of the
participants in academic year 2006 and 34% (47/140) in
academic year 2007 had herpangina.
Infection rate of enteroviruses and serotypes
Confirmed by PCR and/or viral culture, the incidence of
enterovirus infection was 72% (118/163) in academic year









19 (53%) 102 (53%) 0.89
Herpangina 23 (64%) 92 (48%) 0.12
EV: enterovirus.
100 W.-C. Huang et al.2006 and the serotypes were identified in 27% (32/118) of
samples. The incidence of enterovirus infection in
academic year 2007 was 26% (36/140) and the serotypes
among 77% (28/36) of the samples were identifiable. The
serotypes of enteroviruses are presented in Table 1. In
2006, coxsackievirus A4 (44%) and A2 (16%) were the leading
serotypes. Later in 2007, the incidence of coxsackievirus A2
infection increased (39%), which was followed by EV68
(32%). In both academic years, coxsackieviruses A2 and A6
were isolated; however, neither EV71 nor coxsackievirus
A16 was isolated during the study period.
The relation between presence of EV71 antibody
and infections of other enteroviruses
During this period, 64% of the participants (23/36) with
EV71 antibodies had herpangina whereas 48% (92/192) of
the EV71 seronegative group had a history of herpangina
(p Z 0.12).
Furthermore, Table 2 shows the rate of other entero-
virus infections was 53% (19/36) in EV71 seropositive group
and 53% (102/192) in EV71 seronegative group (pZ0.89)
indicating that the participants with or without prior EV71
neutralizing antibody showed a similar incidence of non-71
enterovirus infection.
Discussion
The EV71 seropositive rate was relatively low (20%) in
preschool children in Taipei City between September 2006
and August 2008 in comparison to the pre-endemic
(22e36%) and post-endemic seroprevalence (24e42%) in
children 2e5 years of age in the whole country before and
after the 1998 outbreak.10 Low seropositivity and absence
of EV71 seroconversion in our study might indicate the
infrequency of EV71 circulation in Taipei City during the
period of investigation. This result also suggests the accu-
mulation of susceptible hosts of EV71. Moreover, we found







CA1 0 (0) 1 (4)
CA2 5 (16) 11 (39)
CA4 14 (44) 0 (0)
CA6 2 (6) 1 (4)
CA9 1 (3) 0 (0)
CA10 0 (0) 2 (7)
CB2 3 (9) 0 (0)
CB4 0 (0) 4 (14)
Echo 4 3 (9) 0 (0)
Echo 6 4 (13) 0 (0)
EV68 0 (0) 9 (32)
Total 32 (100) 28 (100)
CA: coxsackie A virus; CB: coxsackie B virus; EV: enterovirus.a similar incidence of acquiring non-EV71 enterovirus
infection. Herpangina occurred more frequently in children
with EV71 antibodies than in the seronegative group but the
difference was insignificant. This showed that previous
EV71 infection or the presence of EV71 neutralizing anti-
body did not have a strong impact on decreasing the inci-
dence of EV infection caused by other serotypes.
In our study, the incidence of EV71 seropositivity
increased with age, which might indicate transmission was
more frequent among elder children in kindergarten
because of increased interpersonal activities. This finding
was also observed in the studies before the 1998 EV71
endemics in Taiwan in much larger populations,10,12 which
presented as an epidemiologic feature among preschool
children. Furthermore, we noted that the presence of EV71
antibodies was not associated with lower risks of non-71 EV
infection, especially the infection of class A non-polio
enteroviruses (e.g., coxsackievirus A2, A4, A6 and A10),
which shared more RNA homology with EV71. In a recent
murine study, passive immunization of avirulent EV71 or
coxsackievirus A16 induced antiEV71 antibodies with
neutralizing activity. This study, nevertheless, did not
observe the crossprotection toward coxsackievirus B3 or
poliovirus.15 The prior pre-endemic research reported that
a higher seroprevalence rate of EV71 antibodies might be
associated with minor clinical symptoms of EV71 infection
among elder children and adolescents, which suggested
greater humoral protection.9,10 In our viral surveillance,
however, there was no infection related to EV71 or cox-
sackievirus A16. Due to the absence of circulating EV71 and
coxsackievirus A16 in our research period, the relation
between seroprevalence and crossprotection of EV71 anti-
bodies was undetermined. Thus, our finding could be a lead
for further investigations to clarify the circumstantial
influences by expanding the population and extending the
study periods.
In our investigation, coxsackievirus A4 was the most
common serotype in academic year 2006 and coxsackievirus
A2 had the highest incidence in academic year 2007. In both
years, none of our participants had virological-confirmed
infections of EV71 or coxsackievirus A16. According to the
analysis from the Center of Disease Control (CDC) in
Taiwan, the number of cases of severe EV infection were
significantly higher than usual in 2000 (291 cases), 2001 (393
cases) and 2005 (142 cases) but the number dramatically
declined in 2006 (11 cases) and in 2007 (12 cases). Cox-
sackievirus A16 and EV71 were the two prevailing serotypes
between 1998 and 2005, followed by coxsackievirus B3,
echovirus 4, coxsackievirus B4.16 The most common sero-
types in the following years were coxsackievirus A4 in 2006,
Enteroviruses among kindergarteners 101coxsackievirus A16 in 2007 and coxsackievirus A2 in 2008.
EV71 accounted for 12% (330/2728) of confirmed EV infec-
tion in Taiwan in 2005 and its incidence markedly dropped
to 0.05% (1/1995) and 0.6% (16/2471) in 2006 and 2007
respectively. Coxsackievirus A16 presented similar findings.
In 2005, the incidence of coxsackievirus A16 infection was
26% (696/2728). It decreased to 3% (60/1995) in 2006 but
rebounded to 23% (578/2471) in 2007. These findings were
further evidence that since 2005 the circulation of EV71 has
become less constant, which was related to the absence of
seroconversion in our study population.
At the time our project ended, unfortunately, an EV
epidemic recurred in the summer of 2008. In the annual
report of CDC in Taiwan, by December 2008, 3677 cases of
EV infection were confirmed, 369 cases presented with
severe complications (227 males and 142 females) and 90%
were under 5 years of age. Fourteen cases died during this
endemic. Coxsackievirus A2 (33%, 1199/3677) and EV71
(26%, 966/3677) are the two leading serotypes, followed by
coxsackievirus B4 (10%, 382/3677) and undifferentiated
non-polio enteroviruses (9%, 338/3677).17 Therefore, low
seropositivity and seroconversion of EV71 in high risk group,
indicating large number of susceptible hosts, may be
considered an indicator of EV71 endemic as Lu et al.
previously suggested.12
We performed the study in Taipei City, where there were
fewer cases of EV71 compared with other areas in Taiwan.
EV infection more frequently occurs in tropical climates
with higher humidity. Further investigations of seropreva-
lence in other regions are necessary to unfold the effect of
environmental varieties. Also, an extension of the study
period may elucidate the mystery that contributes to the
EV71 outbreak.
We found the presence of EV71 neutralizing antibody did
not lower the risks of enterovirus infection by other sero-
types and further monitoring of EV activity is needed to
control its spread.
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